S&P 500   2,995.68 (+1.00%)
DOW   27,024.80 (+0.89%)
QQQ   193.52 (+1.27%)
AAPL   235.32 (-0.23%)
FB   188.89 (+3.06%)
MSFT   141.58 (+1.45%)
GOOGL   1,242.24 (+2.01%)
AMZN   1,767.38 (+1.78%)
CGC   20.10 (+6.57%)
NVDA   196.37 (+5.28%)
MU   46.46 (+3.54%)
BABA   175.29 (+2.41%)
GE   8.89 (+1.95%)
TSLA   257.89 (+0.36%)
AMD   30.72 (+0.62%)
T   37.90 (+1.15%)
F   9.07 (+2.83%)
ACB   3.76 (+7.12%)
PRI   123.67 (+1.81%)
NFLX   284.25 (-0.45%)
BAC   29.73 (+2.02%)
GILD   65.30 (+1.22%)
DIS   129.76 (+0.05%)
S&P 500   2,995.68 (+1.00%)
DOW   27,024.80 (+0.89%)
QQQ   193.52 (+1.27%)
AAPL   235.32 (-0.23%)
FB   188.89 (+3.06%)
MSFT   141.58 (+1.45%)
GOOGL   1,242.24 (+2.01%)
AMZN   1,767.38 (+1.78%)
CGC   20.10 (+6.57%)
NVDA   196.37 (+5.28%)
MU   46.46 (+3.54%)
BABA   175.29 (+2.41%)
GE   8.89 (+1.95%)
TSLA   257.89 (+0.36%)
AMD   30.72 (+0.62%)
T   37.90 (+1.15%)
F   9.07 (+2.83%)
ACB   3.76 (+7.12%)
PRI   123.67 (+1.81%)
NFLX   284.25 (-0.45%)
BAC   29.73 (+2.02%)
GILD   65.30 (+1.22%)
DIS   129.76 (+0.05%)
Log in

Adamas Pharmaceuticals Stock Price, News & Analysis (NASDAQ:ADMS)

$4.03
+0.13 (+3.33 %)
(As of 10/15/2019 04:00 PM ET)
Today's Range
$3.85
Now: $4.03
$4.04
50-Day Range
$3.46
MA: $5.67
$7.52
52-Week Range
$3.35
Now: $4.03
$19.30
Volume501,894 shs
Average Volume504,702 shs
Market Capitalization$111.92 million
P/E RatioN/A
Dividend YieldN/A
Beta1.6
Adamas Pharmaceuticals, Inc focuses on the discovery, development, and commercialization of medicines for patients suffering from chronic neurologic disorders. The company offers GOCOVRI, an extended release capsule for the treatment of dyskinesia in patients with Parkinson's disease receiving levodopa-based therapy, with or without concomitant dopaminergic medications. Read More…

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:ADMS
CUSIPN/A
Phone510-450-3500

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$34.05 million
Book Value$3.29 per share

Profitability

Net Income$-131,000,000.00
Net Margins-241.41%

Miscellaneous

Employees159
Market Cap$111.92 million
Next Earnings Date11/7/2019 (Estimated)
OptionableOptionable

Receive ADMS News and Ratings via Email

Sign-up to receive the latest news and ratings for ADMS and its competitors with MarketBeat's FREE daily newsletter.


Adamas Pharmaceuticals (NASDAQ:ADMS) Frequently Asked Questions

What is Adamas Pharmaceuticals' stock symbol?

Adamas Pharmaceuticals trades on the NASDAQ under the ticker symbol "ADMS."

How were Adamas Pharmaceuticals' earnings last quarter?

Adamas Pharmaceuticals Inc (NASDAQ:ADMS) posted its earnings results on Thursday, August, 8th. The specialty pharmaceutical company reported ($0.90) EPS for the quarter, topping the consensus estimate of ($0.98) by $0.08. The specialty pharmaceutical company had revenue of $12.69 million for the quarter, compared to analyst estimates of $12.62 million. Adamas Pharmaceuticals had a negative return on equity of 149.97% and a negative net margin of 241.41%. View Adamas Pharmaceuticals' Earnings History.

When is Adamas Pharmaceuticals' next earnings date?

Adamas Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Thursday, November 7th 2019. View Earnings Estimates for Adamas Pharmaceuticals.

What price target have analysts set for ADMS?

10 Wall Street analysts have issued 12 month price objectives for Adamas Pharmaceuticals' shares. Their predictions range from $5.00 to $55.00. On average, they expect Adamas Pharmaceuticals' share price to reach $18.44 in the next year. This suggests a possible upside of 357.7% from the stock's current price. View Analyst Price Targets for Adamas Pharmaceuticals.

What is the consensus analysts' recommendation for Adamas Pharmaceuticals?

10 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Adamas Pharmaceuticals in the last year. There are currently 2 sell ratings, 3 hold ratings and 5 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Adamas Pharmaceuticals.

Has Adamas Pharmaceuticals been receiving favorable news coverage?

Media stories about ADMS stock have trended neutral recently, according to InfoTrie. The research firm identifies positive and negative news coverage by reviewing more than six thousand blog and news sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores closest to five being the most favorable. Adamas Pharmaceuticals earned a media sentiment score of 0.4 on InfoTrie's scale. They also gave media coverage about the specialty pharmaceutical company a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an effect on the company's share price in the immediate future. View News Stories for Adamas Pharmaceuticals.

Are investors shorting Adamas Pharmaceuticals?

Adamas Pharmaceuticals saw a decrease in short interest during the month of September. As of September 30th, there was short interest totalling 2,010,000 shares, a decrease of 16.6% from the August 30th total of 2,410,000 shares. Based on an average daily volume of 540,000 shares, the short-interest ratio is currently 3.7 days. Currently, 9.2% of the shares of the stock are short sold. View Adamas Pharmaceuticals' Current Options Chain.

Who are some of Adamas Pharmaceuticals' key competitors?

What other stocks do shareholders of Adamas Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Adamas Pharmaceuticals investors own include Rite Aid (RAD), Omeros (OMER), Sangamo Therapeutics (SGMO), Exelixis (EXEL), TG Therapeutics (TGTX), ACADIA Pharmaceuticals (ACAD), Adamis Pharmaceuticals (ADMP), Amarin (AMRN), Synergy Pharmaceuticals (SGYP) and Century Aluminum (CENX).

Who are Adamas Pharmaceuticals' key executives?

Adamas Pharmaceuticals' management team includes the folowing people:
  • Dr. Gregory T. Went, Co-Founder, Chairman & CEO (Age 55)
  • Mr. Alfred G. Merriweather, Chief Financial Officer (Age 65)
  • Mr. Christopher B. Prentiss, Chief Accounting Officer (Age 44)
  • Ashleigh Barreto, Director of Corp. Communications & Investor Relations
  • Ms. Jennifer J. Rhodes, Chief Bus. Officer, Gen. Counsel, Chief Compliance Officer & Corp. Sec. (Age 49)

How do I buy shares of Adamas Pharmaceuticals?

Shares of ADMS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Adamas Pharmaceuticals' stock price today?

One share of ADMS stock can currently be purchased for approximately $4.03.

How big of a company is Adamas Pharmaceuticals?

Adamas Pharmaceuticals has a market capitalization of $111.92 million and generates $34.05 million in revenue each year. The specialty pharmaceutical company earns $-131,000,000.00 in net income (profit) each year or ($4.87) on an earnings per share basis. Adamas Pharmaceuticals employs 159 workers across the globe.View Additional Information About Adamas Pharmaceuticals.

What is Adamas Pharmaceuticals' official website?

The official website for Adamas Pharmaceuticals is http://www.adamaspharma.com/.

How can I contact Adamas Pharmaceuticals?

Adamas Pharmaceuticals' mailing address is 1900 POWELL ST. SUITE 1000, EMERYVILLE CA, 94608. The specialty pharmaceutical company can be reached via phone at 510-450-3500 or via email at [email protected]


MarketBeat Community Rating for Adamas Pharmaceuticals (NASDAQ ADMS)

Community Ranking:  2.7 out of 5 (star star)
Outperform Votes:  345 (Vote Outperform)
Underperform Votes:  297 (Vote Underperform)
Total Votes:  642
MarketBeat's community ratings are surveys of what our community members think about Adamas Pharmaceuticals and other stocks. Vote "Outperform" if you believe ADMS will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ADMS will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 10/15/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel